Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBIO Generation Bio	$6.00 -2.8%	$4.60	$3.00 ▼ $29.40	$40.41M	2.67	169,084 shs	102,024 shs
PCSA Heatwurx	$0.19 -10.7%	$0.22	$0.15 ▼ $1.50	$9.52M	1.32	8.50 million shs	3.67 million shs
PEPG PepGen	$1.16 -4.9%	$1.28	$0.88 ▼ $10.06	$38.05M	1.19	1.22 million shs	174,531 shs
SNTI Senti Biosciences	$1.47 -5.2%	$1.85	$1.46 ▼ $16.94	$38.46M	2.07	171,893 shs	178,141 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBIO Generation Bio	-2.83%	-1.75%	+39.91%	+64.93%	-75.80%
PCSA Heatwurx	-0.61%	+2.22%	-3.64%	-27.66%	-85.20%
PEPG PepGen	-1.61%	-2.40%	-11.59%	-18.39%	-87.02%
SNTI Senti Biosciences	-0.64%	-2.52%	-13.89%	-49.35%	-39.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBIO Generation Bio	3.3988 of 5 stars	3.3	3.0	2.7	3.3	1.3
PCSA Heatwurx	2.529 of 5 stars	3.3	4.0	1.6	1.7	0.6
PEPG PepGen	3.2833 of 5 stars	3.2	4.0	2.7	2.5	1.3
SNTI Senti Biosciences	3.0247 of 5 stars	3.5	5.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBIO Generation Bio	2.67	Moderate Buy	$10.67	77.78% Upside
PCSA Heatwurx	2.50	Moderate Buy	$2.00	958.20% Upside
PEPG PepGen	2.33	Hold	$7.67	560.92% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	478.23% Upside

Current Analyst Ratings Breakdown

Latest PCSA, GBIO, PEPG, and SNTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	PCSA Heatwurx	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	GBIO Generation Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/13/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $7.00
8/13/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/8/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
7/18/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $70.00
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBIO Generation Bio	$21.23M	1.90	N/A	N/A	$8.03 per share	0.75
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.12 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.17 per share	N/A
SNTI Senti Biosciences	$2.56M	15.02	N/A	N/A	$0.94 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBIO Generation Bio	-$131.67M	-$10.82	N/A	N/A	N/A	-341.12%	-91.07%	-33.65%	11/5/2025 (Estimated)
PCSA Heatwurx	-$11.85M	-$2.32	N/A	N/A	N/A	N/A	-342.36%	-243.48%	10/29/2025 (Estimated)
PEPG PepGen	-$89.98M	-$2.96	N/A	N/A	N/A	N/A	-92.51%	-70.39%	11/6/2025 (Estimated)
SNTI Senti Biosciences	-$52.79M	-$8.95	N/A	N/A	N/A	N/A	-223.98%	-76.02%	11/13/2025 (Estimated)

Latest PCSA, GBIO, PEPG, and SNTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GBIO Generation Bio	-$2.80	-$3.12	-$0.32	-$3.12	$2.51 million	$0.77 million
8/7/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
8/7/2025	Q2 2025	PEPG PepGen	-$0.85	-$0.70	+$0.15	-$0.70	N/A	N/A
8/7/2025	Q2 2025	SNTI Senti Biosciences	-$0.58	-$0.56	+$0.02	-$0.56	$1.30 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBIO Generation Bio	N/A	7.51	7.51
PCSA Heatwurx	N/A	3.45	3.45
PEPG PepGen	N/A	4.74	4.74
SNTI Senti Biosciences	N/A	3.26	3.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBIO Generation Bio	95.22%
PCSA Heatwurx	91.93%
PEPG PepGen	58.01%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
GBIO Generation Bio	21.80%
PCSA Heatwurx	2.40%
PEPG PepGen	5.20%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBIO Generation Bio	150	6.74 million	5.27 million	Optionable
PCSA Heatwurx	20	50.35 million	49.14 million	Not Optionable
PEPG PepGen	30	32.80 million	31.09 million	Not Optionable
SNTI Senti Biosciences	4	26.16 million	25.34 million	Not Optionable

PCSA, GBIO, PEPG, and SNTI Headlines

Recent News About These Companies

Senti Biosciences (NASDAQ:SNTI) Upgraded to Hold at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025 | globenewswire.com

Senti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor Segment

August 12, 2025 | quiverquant.comQ

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

August 12, 2025 | globenewswire.com

Senti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...

August 8, 2025 | finanznachrichten.de

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

August 7, 2025 | globenewswire.com

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

August 5, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/08/05/3127362/0/en/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-of-senti-202-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-including-acute-myeloid-leukemia.html$

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

July 21, 2025 | globenewswire.com

Senti Biosciences, Inc. Appoints Bryan Baum to Board of Directors

July 18, 2025 | quiverquant.comQ

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

July 18, 2025 | globenewswire.com

NASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.com

July 3, 2025 | investing.com

SNTI - Senti Biosciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Senti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight Series

June 30, 2025 | quiverquant.comQ

Senti Bio Participates in Nasdaq Amplify Spotlight Series

June 30, 2025 | globenewswire.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - Nasdaq

June 26, 2025 | nasdaq.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies

June 24, 2025 | quiverquant.comQ

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

June 24, 2025 | globenewswire.com

Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation

June 18, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, GBIO, PEPG, and SNTI Company Descriptions

Generation Bio NASDAQ:GBIO

$6.00 -0.17 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 0.00 (0.00%)

As of 07:37 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Heatwurx NASDAQ:PCSA

$0.19 -0.02 (-10.68%)

Closing price 04:00 PM Eastern

Extended Trading

$0.18 -0.01 (-2.65%)

As of 07:59 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

PepGen NASDAQ:PEPG

$1.16 -0.06 (-4.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.03 (+2.16%)

As of 07:22 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Senti Biosciences NASDAQ:SNTI

$1.47 -0.08 (-5.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 +0.06 (+4.08%)

As of 07:33 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time